Australian drug discovery company, Bionomics Limited (ASX: BNO), announced today that their latest findings indicate that BNC105 disrupts the vasculature in human prostate tumours grown in mice, expanding on its previously demonstrated preclinical efficacy in breast and colon cancers.
